Bay Colony Advisory Group Inc d b a Bay Colony Advisors Has $305,000 Position in iShares Biotechnology ETF (NASDAQ:IBB)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors raised its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 16.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,309 shares of the financial services provider’s stock after buying an additional 322 shares during the quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in iShares Biotechnology ETF were worth $305,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its holdings in shares of iShares Biotechnology ETF by 29.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,380,229 shares of the financial services provider’s stock valued at $346,561,000 after purchasing an additional 538,899 shares in the last quarter. Commerce Bank lifted its holdings in shares of iShares Biotechnology ETF by 1.8% during the 3rd quarter. Commerce Bank now owns 743,366 shares of the financial services provider’s stock valued at $108,234,000 after purchasing an additional 12,921 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of iShares Biotechnology ETF by 32.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock valued at $96,533,000 after purchasing an additional 164,000 shares in the last quarter. Main Management ETF Advisors LLC lifted its holdings in shares of iShares Biotechnology ETF by 2.5% during the 3rd quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock valued at $86,395,000 after purchasing an additional 14,535 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in iShares Biotechnology ETF in the 4th quarter valued at approximately $55,010,000. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Performance

NASDAQ IBB opened at $136.95 on Friday. The stock has a market capitalization of $6.47 billion, a price-to-earnings ratio of 24.52 and a beta of 0.84. The stock’s 50 day moving average price is $136.08 and its two-hundred day moving average price is $140.28. iShares Biotechnology ETF has a 52 week low of $123.60 and a 52 week high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The company also recently announced a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.